How did JAGX's Q4 2024 earnings surprise investors?

**Jaguar Health Inc (JAGX) experienced a significant decline in its Q4 2024 earnings, which likely surprised investors with a negative shock.** Here are the key details:

1. **Earnings Per Share (EPS) Analysis**: The company reported an EPS of -$18.50 for Q4 2024, which is a substantial loss. This figure is significantly lower than the EPS of -$9.92 reported for the quarter ended December 31, 2023. Such a steep decline in EPS would have come as a surprise to investors, who may have expected a better outcome based on the company's previous performance.

2. **Revenue Analysis**: Despite the negative earnings, Jaguar Health Inc reported a 50.7% increase in revenue from the previous year, with total revenue amounting to $3.47 million for the quarter ended December 31, 2024. This revenue growth may have provided some relief to investors, but it was likely overshadowed by the massive loss reported in the same quarter.
3. **Comparative Analysis**: When compared to the previous quarter, Q3 2024, there was an increase of approximately 14% in revenue. This indicates a positive trend in revenue growth, which could have been a slight silver lining for investors. However, the overall negative earnings figure still dominated the narrative.
4. **Investor Sentiment**: The company's stock had experienced a significant decline of 81.1% so far in the year, and the average consensus recommendation from analysts was "strong buy," with a median 12-month price target of $150. This suggests that while the stock may have potential, the current earnings figures are not reflective of the optimism surrounding the company's future prospects.

In conclusion, Jaguar Health Inc's Q4 2024 earnings report was likely a surprise to investors due to the unexpected large loss, despite the company's positive revenue growth. The significant drop in EPS and the resulting negative net income would have been the primary factors contributing to the surprise.